Atyr Pharma Inc. (NASDAQ:LIFE) shares saw strong trading volume on Friday . 561,733 shares were traded during trading, an increase of 137% from the previous session’s volume of 236,978 shares.The stock last traded at $3.18 and had previously closed at $2.97.

A number of research analysts recently commented on the stock. Zacks Investment Research upgraded shares of Atyr Pharma from a “sell” rating to a “hold” rating in a research note on Tuesday, May 24th. BMO Capital Markets reiterated a “hold” rating on shares of Atyr Pharma in a research note on Thursday, May 12th. Finally, William Blair lowered shares of Atyr Pharma from an “outperform” rating to a “market perform” rating in a research note on Thursday, March 31st. Four equities research analysts have rated the stock with a hold rating and one has issued a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus price target of $23.75.

The firm’s market cap is $80.77 million. The stock has a 50-day moving average of $2.85 and a 200-day moving average of $3.96.

Atyr Pharma (NASDAQ:LIFE) last posted its earnings results on Wednesday, May 11th. The company reported ($0.68) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.70) by $0.02. Equities research analysts forecast that Atyr Pharma Inc. will post ($2.79) EPS for the current year.

In other Atyr Pharma news, insider Grove Matsuoka bought 12,412 shares of the stock in a transaction that occurred on Wednesday, May 11th. The shares were acquired at an average price of $3.04 per share, with a total value of $37,732.48. Following the completion of the purchase, the insider now directly owns 2,412 shares in the company, valued at approximately $7,332.48. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

aTyr Pharma, Inc is a clinical-stage biotherapeutics company. The Company is engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its Physiocrine biology, a discovered set of physiological modulators. The Company focuses on the development of Physiocrine-based therapeutics for the treatment of rare diseases, including facioscapulohumeral muscular dystrophy (FSHD) and limb-girdle muscular dystrophy (LGMD) 2B.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.